专题：Cancer Treatment and Pharmacology

This cluster of papers focuses on the chemotherapy-induced peripheral neuropathy (CIPN) experienced by cancer patients, particularly in the context of breast cancer treatment. It covers various aspects such as the neurotoxic effects of taxanes and oxaliplatin, neuroprotective strategies, and the impact of CIPN on the quality of life of patients. Additionally, it discusses the use of microtubule-targeting agents like Eribulin Mesylate in cancer treatment.
最新文献
Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients

article Full Text OpenAlex

Late‐Onset Large Fixed Erythrodysesthesia Plaque due to Docetaxel

article Full Text OpenAlex

Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)

article Full Text OpenAlex

Chemotherapy‐Induced Cardiotoxicity With Frontline BV‐AVD for Hodgkin Lymphoma

article Full Text OpenAlex

Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications

review Full Text OpenAlex

Chelidonine-induced inhibition of FBP1 disrupts M2 macrophage polarization and attenuates breast cancer

article Full Text OpenAlex

Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives

review Full Text OpenAlex

Chemotherapy induced neurotoxicity in cancer survivors assessed through a dual database bibliometric analysis from 2005 to 2025

article Full Text OpenAlex

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial

article Full Text OpenAlex

Feet Cooling As a Preventive Strategy against Chemotherapy-Induced Peripheral Neuropathy in Advanced Breast Cancer Patients: A Randomized Clinical Trial

article Full Text OpenAlex

近5年高被引文献
Pharmacological Reviews

review Full Text OpenAlex 2675 FWCI0

BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

article Full Text OpenAlex 933 FWCI0

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

article Full Text OpenAlex 567 FWCI83.42022928

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

article Full Text OpenAlex 423 FWCI61.96931318

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

article Full Text OpenAlex 416 FWCI92.06514415

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

article Full Text OpenAlex 395 FWCI92.90043738

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

article Full Text OpenAlex 366 FWCI74.1732542

Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer

article Full Text OpenAlex 357 FWCI79.2402844

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

article Full Text OpenAlex 355 FWCI88.86128793

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

review Full Text OpenAlex 346 FWCI116.15804032